Can Early Development Strategies Avoid Later-Stage Disasters?
PharmTech | March 02, 2018
Pfizer CentreOne, a contract development and manufacturing organization (CDMO) specializing in active pharmaceutical ingredients (APIs), has introduced Enviero progesterone to its contract customers. The API is made via a proprietary synthesis that significantly reduces waste, greenhouse gas emissions, and the use of hazardous solvents. Overall, the process reduces overall carbon footprint by more than 70%, and eliminates the use of metal catalysts, according to the company. The process took more than 12 years to develop and uses a biocatalytic process based on plant sterols.